At a Glance
- Company: AbbVie
- Target: Apogee Therapeutics
- Deal value: $10.9 billion
- Lead asset: Zumilokibart (APG777), a half-life-extended anti-IL-13 antibody
- Next steps: Close in Q3 2026 and advance Phase 3 in atopic dermatitis
What happened?
AbbVie has agreed to acquire Apogee Therapeutics in an all-cash deal worth about $10.9 billion, paying $135.11 per share, a premium of nearly 50% to Apogee’s prior closing price. The centrepiece is zumilokibart, Apogee’s subcutaneous, half-life-extended monoclonal antibody against IL-13, which AbbVie says will strengthen its immunology franchise.
Why does it matter?
The acquisition gives AbbVie a late-stage asset that could extend its leadership in inflammatory disease beyond existing blockbusters such as Skyrizi and Rinvoq. Analysts have highlighted the drug’s long-acting dosing profile as a differentiator that could support competitive positioning in atopic dermatitis, asthma and other IL-13-driven diseases.
Who’s behind it?
AbbVie is a major US biopharma company with a deep immunology business and a clear strategy to replenish growth beyond Humira. Apogee is a clinical-stage biotech focused on dermatologic, respiratory and related inflammatory diseases, and the deal adds its full pipeline to AbbVie’s portfolio.
How was it achieved?
Apogee’s lead programme, formerly APG777, posted 16-week Phase 2 APEX data showing meaningful skin clearance and improvements in itch and disease control in moderate-to-severe atopic dermatitis. Apogee had also recently raised $1.3 billion in strategic financing to support late-stage development, including a Phase 3 push, before AbbVie moved to buy the company outright.
What’s next?
Apogee planned to advance zumilokibart into Phase 3 in the second half of 2026, focusing on the mid-dose arm that showed the strongest activity. AbbVie expects the acquisition to close in the third quarter of 2026, after which it will fold Apogee’s programmes into its broader dermatology, respiratory and inflammatory disease strategy.
What are people saying?
AbbVie framed the deal as a way to reinforce its dermatology leadership and accelerate into respiratory and inflammatory programmes tied to IL-13 biology. Market watchers say the transaction gives AbbVie a “pipeline-in-a-product” asset with long-acting dosing potential and broader immunology upside.